STEMI – Medxy AI

Zalunfiban at First Medical Contact for STEMI: Faster Coronary Patency and Better 30‑Day Outcomes but More Minor Bleeding

By MedXY 11/13/2025

In an international randomized trial, subcutaneous zalunfiban given at first medical contact improved pre‑PCI infarct‑related artery patency and reduced the likelihood of a worse 30‑day hierarchical clinical outcome versus placebo, with more mild–moderate bleeding but no increase in severe bleeding.

Cardiology news

Immediate vs Deferred PCI for Nonculprit Lesions in STEMI: Insights from the iMODERN Trial

By MedXY 10/31/2025

The iMODERN trial demonstrates that immediate iFR-guided PCI of nonculprit lesions in STEMI patients offers no significant benefit over deferred stress MRI-guided PCI regarding major cardiac events at 3 years.

Cardiology

Aspirin Versus Clopidogrel After Acute Coronary Syndrome: Insights from STOPDAPT-3 in High-Bleeding Risk and STEMI Patients

By MedXY 09/22/2025

STOPDAPT-3 trial shows aspirin and clopidogrel yield comparable cardiovascular and bleeding outcomes 1 month to 1 year post-PCI in ACS patients, regardless of bleeding risk or STEMI status.

Cardiology news Specialties

Immediate Versus Staged Complete Revascularisation in STEMI with Multivessel Disease: Insights from the OPTION-STEMI Trial

By MedXY 09/21/2025

The OPTION-STEMI trial evaluated the safety and efficacy of immediate versus staged complete revascularisation during index admission in STEMI patients with multivessel disease, finding no non-inferiority of immediate approach at 1 year.

Cardiology Specialties

Decade-Long Insights into Deferred Versus Immediate Stenting in STEMI Patients: DANAMI-3-DEFER Trial Findings

By MedXY 08/17/2025

The 10-year DANAMI-3-DEFER study compared deferred stenting to immediate stenting in STEMI, showing no mortality benefit but reduced heart failure hospitalizations with deferred stenting.

Cardiology Clinical Updates news Specialties

High-Risk Plaques in Non-Culprit Lesions: Comparative Outcomes After NSTEMI and STEMI

By MedXY 08/16/2025

This study examines the morphology of high-risk plaques in non-culprit coronary lesions among NSTEMI and STEMI patients and their impact on clinical outcomes, suggesting comparable prevalence of high-risk features but differing plaque characteristics between these groups.

Cardiology news Specialties

Comparing Long-Term Outcomes of Biodegradable vs. Durable Polymer Everolimus-Eluting Stents in STEMI: Insights from the CONNECT Trial

By MedXY 08/13/2025

The CONNECT trial demonstrates no significant difference in neoatherosclerosis rates 3 years post-STEMI between biodegradable and durable polymer everolimus-eluting stents, challenging assumptions about biodegradable polymers' superiority.